| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2083145 | Drug Discovery Today: Therapeutic Strategies | 2006 | 7 Pages |
Abstract
Hepatitis C virus (HCV) chronic infection represents a worldwide health problem and numerous efforts are invested to develop novel therapies. HCV therapeutic vaccines have started to enter the clinics. The furthest developed vaccines are adjuvanted recombinant antigens or peptides (phase IIb). Whereas their safety has been established, their efficacy remains to be proven. The new wave of vaccines is tailored for induction of robust T-cell immunity and is about to enter the clinics.
Section editors:Gary Woodnutt – CovX, San Diego, USA.Paul-Henri Lambert – Centre of Vaccinology, University of Geneva, Switzerland.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Perrine Martin, Geneviève Inchauspé,